vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $208.9M, roughly 1.6× iRhythm Holdings, Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 2.7%, a 10.5% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $14.5M). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
HAE vs IRTC — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $208.9M |
| Net Profit | $44.7M | $5.6M |
| Gross Margin | 59.7% | 70.9% |
| Operating Margin | 19.9% | 1.1% |
| Net Margin | 13.2% | 2.7% |
| Revenue YoY | -2.7% | 27.1% |
| Net Profit YoY | 19.3% | 518.5% |
| EPS (diluted) | $0.95 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $208.9M | ||
| Q3 25 | $327.3M | $192.9M | ||
| Q2 25 | $321.4M | $186.7M | ||
| Q1 25 | $330.6M | $158.7M | ||
| Q4 24 | $348.5M | $164.3M | ||
| Q3 24 | $345.5M | $147.5M | ||
| Q2 24 | $336.2M | $148.0M | ||
| Q1 24 | — | $131.9M |
| Q4 25 | $44.7M | $5.6M | ||
| Q3 25 | $38.7M | $-5.2M | ||
| Q2 25 | $34.0M | $-14.2M | ||
| Q1 25 | $58.0M | $-30.7M | ||
| Q4 24 | $37.5M | $-1.3M | ||
| Q3 24 | $33.8M | $-46.2M | ||
| Q2 24 | $38.4M | $-20.1M | ||
| Q1 24 | — | $-45.7M |
| Q4 25 | 59.7% | 70.9% | ||
| Q3 25 | 59.5% | 71.1% | ||
| Q2 25 | 59.8% | 71.2% | ||
| Q1 25 | 58.4% | 68.8% | ||
| Q4 24 | 55.5% | 70.0% | ||
| Q3 24 | 54.2% | 68.8% | ||
| Q2 24 | 52.0% | 69.9% | ||
| Q1 24 | — | 66.3% |
| Q4 25 | 19.9% | 1.1% | ||
| Q3 25 | 17.9% | -4.4% | ||
| Q2 25 | 16.8% | -10.0% | ||
| Q1 25 | 21.6% | -20.5% | ||
| Q4 24 | 16.9% | -2.5% | ||
| Q3 24 | 15.0% | -34.1% | ||
| Q2 24 | 11.8% | -15.5% | ||
| Q1 24 | — | -28.9% |
| Q4 25 | 13.2% | 2.7% | ||
| Q3 25 | 11.8% | -2.7% | ||
| Q2 25 | 10.6% | -7.6% | ||
| Q1 25 | 17.5% | -19.3% | ||
| Q4 24 | 10.8% | -0.8% | ||
| Q3 24 | 9.8% | -31.3% | ||
| Q2 24 | 11.4% | -13.6% | ||
| Q1 24 | — | -34.6% |
| Q4 25 | $0.95 | $0.18 | ||
| Q3 25 | $0.81 | $-0.16 | ||
| Q2 25 | $0.70 | $-0.44 | ||
| Q1 25 | $1.17 | $-0.97 | ||
| Q4 24 | $0.74 | $-0.03 | ||
| Q3 24 | $0.66 | $-1.48 | ||
| Q2 24 | $0.74 | $-0.65 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $583.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $152.7M |
| Total Assets | $2.5B | $1.0B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $583.8M | ||
| Q3 25 | $296.4M | $565.2M | ||
| Q2 25 | $292.9M | $545.5M | ||
| Q1 25 | $306.8M | $520.6M | ||
| Q4 24 | $320.8M | $535.6M | ||
| Q3 24 | $299.3M | $522.0M | ||
| Q2 24 | $344.4M | $561.5M | ||
| Q1 24 | — | $569.1M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $152.7M | ||
| Q3 25 | $849.2M | $121.9M | ||
| Q2 25 | $882.3M | $103.7M | ||
| Q1 25 | $820.8M | $86.7M | ||
| Q4 24 | $906.9M | $90.9M | ||
| Q3 24 | $878.9M | $71.8M | ||
| Q2 24 | $905.4M | $99.2M | ||
| Q1 24 | — | $90.3M |
| Q4 25 | $2.5B | $1.0B | ||
| Q3 25 | $2.4B | $995.2M | ||
| Q2 25 | $2.5B | $964.0M | ||
| Q1 25 | $2.5B | $926.1M | ||
| Q4 24 | $2.5B | $931.4M | ||
| Q3 24 | $2.5B | $909.7M | ||
| Q2 24 | $2.5B | $919.2M | ||
| Q1 24 | — | $909.8M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $26.2M |
| Free Cash FlowOCF − Capex | $87.2M | $14.5M |
| FCF MarginFCF / Revenue | 25.7% | 6.9% |
| Capex IntensityCapex / Revenue | 1.9% | 5.6% |
| Cash ConversionOCF / Net Profit | 2.09× | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $26.2M | ||
| Q3 25 | $111.3M | $34.9M | ||
| Q2 25 | $17.4M | $27.7M | ||
| Q1 25 | $116.6M | $-7.9M | ||
| Q4 24 | $43.8M | $19.2M | ||
| Q3 24 | $48.8M | $24.3M | ||
| Q2 24 | $-27.4M | $11.8M | ||
| Q1 24 | — | $-52.0M |
| Q4 25 | $87.2M | $14.5M | ||
| Q3 25 | $106.3M | $20.1M | ||
| Q2 25 | $13.6M | $17.3M | ||
| Q1 25 | $100.9M | $-17.3M | ||
| Q4 24 | $35.2M | $12.4M | ||
| Q3 24 | $39.4M | $15.5M | ||
| Q2 24 | $-33.1M | $3.4M | ||
| Q1 24 | — | $-61.8M |
| Q4 25 | 25.7% | 6.9% | ||
| Q3 25 | 32.5% | 10.4% | ||
| Q2 25 | 4.2% | 9.3% | ||
| Q1 25 | 30.5% | -10.9% | ||
| Q4 24 | 10.1% | 7.5% | ||
| Q3 24 | 11.4% | 10.5% | ||
| Q2 24 | -9.8% | 2.3% | ||
| Q1 24 | — | -46.8% |
| Q4 25 | 1.9% | 5.6% | ||
| Q3 25 | 1.5% | 7.7% | ||
| Q2 25 | 1.2% | 5.6% | ||
| Q1 25 | 4.7% | 5.9% | ||
| Q4 24 | 2.5% | 4.2% | ||
| Q3 24 | 2.7% | 6.0% | ||
| Q2 24 | 1.7% | 5.7% | ||
| Q1 24 | — | 7.4% |
| Q4 25 | 2.09× | 4.70× | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
